# Early Allogeneic Blood Stem Cell Transplantation in High-risk Acute Myeloid Leukemia (AML)

> **NCT00188136** · PHASE2 · COMPLETED · sponsor: **University Hospital Carl Gustav Carus** · enrollment: 32 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Melphalan, ATG, Fludarabine

## Key facts

- **NCT ID:** NCT00188136
- **Lead sponsor:** University Hospital Carl Gustav Carus
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-08
- **Primary completion:** 2010-07
- **Final completion:** 2010-12
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2015-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00188136

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00188136, "Early Allogeneic Blood Stem Cell Transplantation in High-risk Acute Myeloid Leukemia (AML)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00188136. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*